Dr. Jochen H. Lorch, M.D.
Claim this profileNorthwestern University
Area of expertise
Cancer
Jochen H. Lorch, M.D. has run 7 trials for Cancer. Some of their research focus areas include:
Squamous Cell Carcinoma
Jochen H. Lorch, M.D. has run 7 trials for Squamous Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Medicine Cancer Center Warrenville
Clinical Trials Jochen H. Lorch, M.D. is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting
1 award
Phase 2
31 criteria
Targeted Therapy vs. Chemotherapy
for Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Recruiting
2 awards
Phase 3
7 criteria
More about Jochen H. Lorch, M.D.
Clinical Trial Related
5 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Jochen H. Lorch, M.D. has experience with
- Pembrolizumab
- Cisplatin
- Nivolumab
- Carboplatin
- Dabrafenib
- Trametinib
Breakdown of trials Jochen H. Lorch, M.D. has run
Cancer
Squamous Cell Carcinoma
Thyroid Cancer
Head and Neck Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jochen H. Lorch, M.D. specialize in?
Jochen H. Lorch, M.D. focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jochen H. Lorch, M.D. currently recruiting for clinical trials?
Yes, Jochen H. Lorch, M.D. is currently recruiting for 6 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jochen H. Lorch, M.D. has studied deeply?
Yes, Jochen H. Lorch, M.D. has studied treatments such as Pembrolizumab, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Jochen H. Lorch, M.D.?
Apply for one of the trials that Jochen H. Lorch, M.D. is conducting.
What is the office address of Jochen H. Lorch, M.D.?
The office of Jochen H. Lorch, M.D. is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.